Thymosin Beta-4 Fragment 17-23
Evidence Grade C — Moderate human evidence. 14 published studies, 11 human. 0 registered clinical trials.
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. It is often marketed as equivalent to full-length thymosin beta-4, but a 7-amino-acid fragment and a 43-amino-acid protein are pharmacologically distinct molecules. No human clinical trials of TB-500 specifically have been conducted. It is prohibited by WADA.
14 published studies: 11 human, 3 animal, 5 in-vitro, 3 reviews
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent.
TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
TB-500 contains the actin-binding motif (LKKTETQ) from its parent protein thymosin beta-4. Research in animal models and cell culture suggests this fragment may interact with cellular structural proteins. These observations have not been replicated or validated in human studies. The compound is often marketed in grey-market channels as equivalent to full-length thymosin beta-4, but a 7-amino-acid fragment and a 43-amino-acid protein are pharmacologically distinct molecules.
No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which cannot be assumed to have equivalent effects. TB-500 is known primarily from equine and greyhound racing contexts. A theoretical concern exists around promoting blood vessel growth in tumours (biologically plausible given the mechanism, though not demonstrated). The absence of any human safety, efficacy, interaction, or dosing data means the compound's effects in humans are entirely unknown. Products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
ARA-290 (cibinetide) has no marketing authorisation. Phase II trials in sarcoidosis neuropathy showed improvements in corneal nerve fibre density, and a Phase II trial in diabetic neuropathy reported improved metabolic parameters and pain scores. The FDA granted Fast Track designation for sarcoidosis neuropathy. No Phase III trials have been completed. The compound represents an investigational approach to tissue repair that is distinct from existing erythropoietin-based therapies, but its clinical development remains at an early stage.
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
Chonluten has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies, including one Western-collaborated publication. The Western-collaborated study represents a higher standard of evidence than many Khavinson bioregulator publications, but remains a single in vitro study without clinical confirmation. Products available through unregulated channels lack pharmaceutical quality assurance.
